Stock Analysis
Vera Therapeutics, Inc. (VERA) Stock Analysis
Vera Therapeutics, Inc. (VERA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Vera Therapeutics, Inc. (VERA) currently has an AIQ Score of 42/100, indicating a neutral setup. Risk is the strongest factor at 57/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
VERA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $35.05 |
| AIQ Score | 42/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.46B |
| P/E Ratio | -5.84 |
| Forward P/E | — |
| EPS | -$1.52 |
| Revenue TTM | $0 |
| Dividend Yield | 0.00% |
| Beta | 0.95 |
| Volume | 3.8M |
| 52-week range | $22.72-$56.05 |
| RSI 14 | 59.79 |
| 50-Day SMA | $35.22 |
| 200-Day SMA | $39.56 |
| Analyst Price Target | $86.75 |
| Next Earnings | Nov 4, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
VERA
OverviewVERA Stock Analysis Summary
Vera Therapeutics, Inc. (VERA) currently has an AIQ Score of 42/100, indicating a neutral setup. Risk resilience is the strongest factor at 57/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, VERA has AIQ Score of 42/100 with Risk resilience base of 57/100 and fading Quality at 27/100. Wait for component alignment before adding exposure.
Risk resilience (57/100) leads while Quality (27/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 4.32% stock move · VERA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is VERA Bullish or Bearish Right Now?
VERA currently has a neutral overall setup. Risk Resilience is the strongest factor at 57/100, while Quality is weakest at 27/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +147.50% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (31 vs 7).
- - Price is -11.40% below its 200-day SMA.
Current Consensus
VERA's Technical Analysis Consensus is currently Strong Buy, with 31 buy, 7 neutral, and 7 sell votes. VERA's 14-day RSI is 59.79, which places the stock in a constructive momentum range. VERA's beta is 0.95, indicating market sensitivity broadly in line with the market.
What Changed in VERA?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the VERA Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
VERA Decision Framework
Public evidence layers, setup checks, and risk context for Vera Therapeutics, Inc..
Vera Therapeutics, Inc. (VERA) Stock Analysis
Vera Therapeutics, Inc. has an AIQ Score of 42/100 in a Neutral regime. Risk is strongest at 57/100. Beta is 0.95, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | VERA is in a Neutral AIQ regime with score 42/100. |
| Signal Conflict | The primary conflict is that risk leads at 57/100 while quality lags at 27/100. |
| Factor Evidence | Momentum 50/100 · Quality 27/100 · Risk 57/100 · Sentiment 53/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 57/100.
Momentum is 50/100 and RSI (14) is 59.8.
VERA is in a Neutral regime at 42/100.
Risk factor is 57/100 with beta 0.95 and annual volatility 59.41%.
Current conflict: risk leads at 57/100 while quality lags at 27/100.
VERA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
VERA Fundamentals
VERA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
VERA Technical Analysis
VERA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
VERA Stock Catalysts
Track VERA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
VERA Dividend Analysis
VERA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
VERA Financial Data
VERA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
VERA Risk Analysis
VERA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
VERA Stock News
VERA stock news, market tone, recent headlines, and catalyst context.
VERA vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: VERA · VRNA · WVE · XNCR · ACAD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| VERA Current stock | 42/100 | — | 50/100 | 57/100 | 0.84 | 59.41% | Current |
| VRNA Verona Pharma | 43/100 | 34/100 | — | 54/100 | 1.41 | 41.05% | VERA vs VRNA |
| WVE Wave Life Sciences | 40/100 | 34/100 | 25/100 | 40/100 | 0.26 | 168.13% | VERA vs WVE |
| XNCR Xencor | 45/100 | 34/100 | 47/100 | 55/100 | 1.88 | 67.18% | VERA vs XNCR |
| ACAD Acadia Pharmaceuticals | 67/100 | 57/100 | 47/100 | 71/100 | 0.5 | 37.75% | VERA vs ACAD |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching VERA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for VERA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
VERA Stock FAQ
What is VERA stock price today?
Vera Therapeutics, Inc.'s current stock price is $35.05. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is VERA bullish or bearish right now?
VERA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is VERA's market cap?
VERA's market cap is $2.46B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is VERA's current P/E ratio?
VERA's current P/E ratio is -5.84 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is VERA's RSI?
VERA's 14-day RSI is 59.79 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is VERA above its 50-day and 200-day moving averages?
VERA is -0.47% from its 50-day SMA and -11.40% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is VERA's next earnings date?
VERA's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does VERA pay a dividend?
VERA's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.